ABSTRACT
Toxoplasmosis can be a severe opportunistic infection in patients with acquired immunodeficiency syndrome (AIDS), and also among solid organ transplant and allogeneic hematopoietic stem cell transplant (HSCT) patients. Patients with low-grade or chronic hematologic malignancies are treated with increasing immunosuppressive regimens and, therefore, represent an emerging population at risk for opportunistic diseases. We report here two cases of disseminated toxoplasmosis occurring in non-allografted hematologic patients with chronic lymphoproliferations. A review of 44 cases from the literature reveals that toxoplasmosis occurs increasingly in indolent B cell lymphoproliferative disorders. Aggressive lymphoproliferations, adenosine analogs, autologous HSCT, and the absence of chemoprophylaxis are the main risk factors for opportunistic toxoplasmosis. The central nervous system is the main organ involved. Fever is only present in half of all cases. Latent Toxoplasma cysts reactivation (LTCR) is the most common, but primary infection occurs in about 20% of cases. Global mortality is over 50%.
Subject(s)
Hematologic Neoplasms/complications , Toxoplasma/isolation & purification , Toxoplasmosis/diagnosis , Toxoplasmosis/pathology , Aged , Female , Humans , Male , Middle Aged , Risk Factors , Toxoplasmosis/parasitologyABSTRACT
OBJECTIVES: To compare virological effectiveness in patients who continued on a virologically successful first-line boosted protease inhibitor (PI)-containing combination antiretroviral therapy (cART) regimen or who switched to a PI-free cART including efavirenz, nevirapine or abacavir. METHODS: From the French Hospital Database on HIV, we selected 439 patients with undetectable viral load (VL) on a first-line boosted PI-containing cART regimen who switched to a PI-free combination including efavirenz, nevirapine or abacavir. Each of these patients was matched with three patients who continued to take their first-line cART regimen, on the basis of gender, age, CD4 cell count, VL, date of cART initiation and the duration of VL undetectability. Time to virological failure (VF) was analysed with Kaplan-Meier curves and Cox models. RESULTS: The 12 month probabilities of VF were 3.7% and 5.7% in non-switch and switch patients, respectively, and 3.9%, 7.2% and 9.0% in patients switching to efavirenz-, nevirapine- and abacavir-containing cART, respectively. After adjustment, only patients switching to abacavir-containing cART had a higher risk of VF than non-switch patients (adjusted hazard ratio, 1.99; 95% confidence interval, 1.05-3.79). CONCLUSIONS: Switching from a virologically successful first-line boosted PI-containing cART regimen to a non-nucleoside reverse transcriptase inhibitor-containing cART regimen containing either efavirenz or nevirapine is virologically safe, while switching to abacavir-containing cART should be avoided.
Subject(s)
Anti-HIV Agents/administration & dosage , Antiretroviral Therapy, Highly Active/methods , HIV Infections/drug therapy , HIV/isolation & purification , Viral Load , Adult , Alkynes , Benzoxazines/administration & dosage , Cohort Studies , Cyclopropanes , Dideoxynucleosides/administration & dosage , Female , HIV Protease Inhibitors/administration & dosage , Humans , Male , Nevirapine/administration & dosage , Prospective Studies , Treatment OutcomeABSTRACT
PURPOSE: Questionnaires assessing patient-reported outcomes in HIV are either too long or not HIV-specific. Our aim was to develop and validate a simplified HIV patient questionnaire. METHOD: 607 HIV patients treated with a combination of antiretroviral (ARV) drugs were enrolled in an observational, longitudinal study. Questionnaires covering health-related quality of life (HRQoL), satisfaction, tolerability, and adherence were administered at baseline (BL) and Month 3 (M3). The items were selected according to their content and discriminant properties. The simplified questionnaire was then administered at Month 12 (M12). Psychometric properties of physical wellbeing, psychological well-being, and global HRQoL scores were assessed. RESULTS: The simplified questionnaire included 12 HRQoL items, 13 side-effects items, and one visual analog scale (VAS) measuring adherence. The principal component analysis (PCA) confirmed the validity of the global HRQoL score. The multivariate analysis showed acceptable-to-good internal consistency of the three scores. Convergent and discriminant validity were excellent for the physical score. The global score showed significant differences according to time since diagnosis, hepatitis coinfection, CD4 count, and viral load. CONCLUSION: This questionnaire deals with the major aspects of HIV patient perceptions. The global HRQoL score is well correlated to the surrogate markers of HIV. Such a questionnaire may represent a new tool for the therapeutic management of HIV-infected patients. Further steps are required to complete these results.
Subject(s)
HIV Infections/drug therapy , HIV Infections/psychology , HIV , Surveys and Questionnaires , Antiretroviral Therapy, Highly Active , HIV Infections/virology , Humans , Logistic Models , Longitudinal Studies , Patient Compliance/psychology , Patient Satisfaction , Quality of Life , Treatment OutcomeABSTRACT
Despite the wide armamentarium available against the human immunodeficiency virus, the efficacy of therapeutic molecules is reduced by the selection of resistant viral strains. Several data argue in favour of an early control of viral replication ever since the first treatment: the intensity of the initial viral replication, as well as results of studies on antiretroviral drugs given as first line treatment and on the early inhibitory response of viral replication. Although an early control is essential for long-term antiviral success, the optimal time limit for the virologic response still needs to be established early knowledge of the virologic response could prove useful in the evaluation of new and more successful therapeutic combinations. Nevertheless, the impact of an earlier control of viral replication on long-term treatment efficacy and on the prevention of resistance emergence deserves further investigation.
Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , Humans , Prognosis , Time FactorsSubject(s)
Amoxicillin/adverse effects , Anti-Bacterial Agents/adverse effects , Meningitis, Aseptic/chemically induced , Meningoencephalitis/chemically induced , Aged , Aged, 80 and over , Cerebrospinal Fluid/chemistry , Cerebrospinal Fluid/metabolism , Cheyne-Stokes Respiration/chemically induced , Drug Hypersensitivity/etiology , Humans , Male , Meningitis, Aseptic/diagnosis , Meningoencephalitis/diagnosisABSTRACT
OBJECTIVES: To investigate the extent of functional T cell recovery and to characterize plasma virus and virus producing cells in patients with increasing CD4 cell counts despite virological failure during protease inhibitor (PI) based therapy. METHODS: The study group included 13 patients who were treated for at least 12 months with a PI based regimen and were selected on the basis of a sustained immunological response (increase of > 70 CD4 cells/microL) despite virological failure (< 1 log10 copies/mL decrease in HIV-1 RNA plasma levels). RESULTS: Compared to a historical series of 11 complete responders with less advanced disease, the proportion of memory CD4 T cells was significantly higher (67.8+/-17.8 vs. 52.8+/-11.0; P=0.045) and the proportion of naive CD4 T cells significantly lower (30.5+/-14.8 vs. 45.0+/-10.4, P=0.021) in patients who were immunological responders/virological nonresponders. In those patients, ongoing viral replication was associated with a strong activation of circulating CD8 T lymphocytes; interleukin-2 production remained decreased. CD4 T cell reactivity to cytomegalovirus proteins was observed in nine of 11 patients tested. In the study group, the proportion of infectious virus present in plasma as well as the levels of intracellular viral replication were similar to those measured in untreated patients. Virological failure in this group of patients probably resulted from pre-existing mutations in the reverse transcriptase gene. CONCLUSIONS: This study of patients with increasing CD4 cell numbers despite virological failure shows the persistence of immune activation and partial immune restoration with no evidence of specific viral dynamics in vivo.
Subject(s)
CD4-Positive T-Lymphocytes/immunology , HIV Infections/immunology , HIV Protease Inhibitors/pharmacology , HIV-1/immunology , Adult , Antiretroviral Therapy, Highly Active , CD4-Positive T-Lymphocytes/cytology , CD4-Positive T-Lymphocytes/drug effects , Cytokines/biosynthesis , Cytokines/blood , DNA, Viral/chemistry , DNA, Viral/genetics , Flow Cytometry , HIV Infections/drug therapy , HIV Infections/virology , HIV Protease Inhibitors/immunology , HIV Protease Inhibitors/therapeutic use , HIV-1/genetics , HIV-1/growth & development , Humans , Longitudinal Studies , Lymphocyte Count , Male , Middle Aged , RNA, Viral/blood , RNA, Viral/genetics , RNA, Viral/immunology , Reverse Transcriptase Polymerase Chain Reaction , Sequence Analysis, DNA , Statistics, NonparametricABSTRACT
We analyzed the kinetics of CD4 cells, human immunodeficiency virus (HIV) viral load, and autoantibodies in acquired immune deficiency syndrome patients with Graves' disease (GD) after immune restoration on highly active antiretroviral therapy (HAART; retrospective study). Five patients (median age, 41 yr) were diagnosed with GD after 20 (range, 14-22) months on HAART on the basis of clinical and biological hyperthyroidism, diffuse hyperfixation of thyroid scan, and the presence of anti-TSH receptor (anti-TSHR) antibodies (Ab). GD was diagnosed several months after the plasma HIV ribonucleic acid load became undetectable, when the CD4+ cell count had risen from 14 (range, 0-62) to 340 (range, 163-460) x 10(6) cells/L. Antithyroid peroxidase (anti-TPO) and anti-TSHRAb appeared 14 (range, 9-18) and 14 (range, 11-20) months after starting HAART and 12 (range, 6-15) and 11 (range, 9-17) months after the increase in CD4+ cells. In 3 patients, TPOAb preceded TSHRAb by 3-10 months. No other autoantibodies were detected. Thyroid antibodies were absent in a group of 55 HIV-1-positive patients with comparable response to HAART and no symptoms of hyperthyroidism (cross-sectional study). Thyroid-specific autoimmunity can occur upon immune restoration with HAART. Our observations suggest a relationship between thymus-dependent immune reconstitution after immunosuppression and autoimmunity and may provide insight into the pathophysiology of GD.
Subject(s)
Autoantibodies/blood , Graves Disease/complications , Graves Disease/immunology , HIV Infections/complications , HIV Infections/immunology , Immunoglobulins, Thyroid-Stimulating/blood , Adult , Antiretroviral Therapy, Highly Active , Antiviral Agents/therapeutic use , CD4 Lymphocyte Count , Female , Graves Disease/blood , HIV Infections/drug therapy , HIV-1/isolation & purification , Humans , Iodide Peroxidase/immunology , Male , RNA, Viral/blood , Receptors, Thyrotropin/immunology , Thyrotropin/blood , Thyroxine/blood , Time Factors , Viral LoadABSTRACT
OBJECTIVES: To investigate whether low ganciclovir serum levels in patients on maintenance oral ganciclovir therapy are associated with recurrence of CMV retinitis. METHODS: A prospective study of the plasma concentration of ganciclovir after initiation of maintenance oral ganciclovir therapy in 14 AIDS patients who had recovered from acute cytomegalovirus (CMV) retinitis. RESULTS: Five of the 14 patients exhibited a mean time to recurrence of 37 days. The mean trough plasma concentration of ganciclovir in these patients after 1 month of oral ganciclovir therapy, was 0.40 +/- 0.30 mg/L. Nine patients had a mean time of progression of 263 days. The mean trough plasma concentration of ganciclovir in the latter patients was 0.80 +/- 0.60 mg/L. CONCLUSIONS: Patients exhibiting trough plasma levels of ganciclovir below 0.6 mg/L may be at higher risk of progression than patients who exhibited levels above 0.6 mg/L.
Subject(s)
AIDS-Related Opportunistic Infections/blood , Acquired Immunodeficiency Syndrome/complications , Antiviral Agents/pharmacokinetics , Cytomegalovirus Retinitis/blood , Ganciclovir/pharmacokinetics , AIDS-Related Opportunistic Infections/complications , AIDS-Related Opportunistic Infections/prevention & control , Acquired Immunodeficiency Syndrome/blood , Acquired Immunodeficiency Syndrome/virology , Acute Disease , Administration, Oral , Antiviral Agents/blood , Antiviral Agents/therapeutic use , Cytomegalovirus/drug effects , Cytomegalovirus Retinitis/complications , Cytomegalovirus Retinitis/prevention & control , Drug Resistance , Ganciclovir/blood , Ganciclovir/therapeutic use , Humans , Prospective Studies , RecurrenceSubject(s)
Acquired Immunodeficiency Syndrome/drug therapy , Anti-HIV Agents/administration & dosage , Autoimmune Diseases/immunology , Graves Disease/immunology , Immunity/drug effects , Adult , Anti-HIV Agents/adverse effects , CD4-Positive T-Lymphocytes/immunology , Female , Humans , Indinavir/administration & dosage , Indinavir/adverse effects , Lamivudine/administration & dosage , Lamivudine/adverse effects , Male , Ritonavir/administration & dosage , Ritonavir/adverse effects , Stavudine/administration & dosage , Stavudine/adverse effectsSubject(s)
Diarrhea/microbiology , Klebsiella Infections/pathology , Klebsiella pneumoniae/pathogenicity , Occult Blood , Aged , Diarrhea/drug therapy , Diarrhea/pathology , Female , HeLa Cells , Humans , Klebsiella Infections/drug therapy , Klebsiella Infections/microbiology , Klebsiella pneumoniae/drug effectsABSTRACT
We report on a cross-sectional study of virological and immunological surrogate markers of HIV infection in 115 patients for whom a determination of the pol 215 and pol 41 zidovudine (ZDV) resistance mutations had been described between January 1995 and February 1996. The patients received ZDV alone or a combination of ZDV and zalcitabine or didanosine. A total of 55, 15 and 45 patients exhibited a wild (W), a mixed (MIX) or a mutant (M) genotype at codon pol 215, respectively; 85, 10 and 20 patients exhibited a W, a MIX or a M genotype at codon pol 41, respectively. Patients exhibiting the pol 215 M genotype had lower CD4 cells, higher plasma viral load and higher proviral burden than patients exhibiting the pol 215 W genotype. Patients who had variants exhibiting both pol 215 M and pol 41 M or MIX genotypes had significantly worsened surrogate marker values than patients having variants only carrying the pol 215 M genotype. These observations demonstrate that the two mutations additively associate with pejorative surrogate markers.
Subject(s)
CD4 Lymphocyte Count , HIV Infections/genetics , HIV-1/isolation & purification , Mutation/genetics , Adult , Anti-HIV Agents/therapeutic use , Biomarkers , Cross-Sectional Studies , Didanosine/therapeutic use , Drug Resistance, Microbial/genetics , Drug Therapy, Combination , Female , Genotype , HIV Infections/drug therapy , HIV Infections/immunology , HIV Infections/virology , Humans , Longitudinal Studies , Male , RNA, Viral , Viral Load , Zalcitabine/therapeutic use , Zidovudine/therapeutic useABSTRACT
A small number of cases of human immunodeficiency virus (HIV) infection have been reported in individuals with no identified risk factors for transmission. We report on the seroconversion of the 61-year-old mother and the subsequent finding of HIV seropositivity in the 66-year-old father of a 31-year-old AIDS patient. Extensive investigation failed to identify any risk factor for intrafamilial transmission. We conducted a genetic analysis and determined the amino acid signature patterns of the V3, V4, and V5 hypervariable domains and flanking regions in the HIV-1 gp120 env gene of 26 clones derived from proviral DNA in peripheral blood mononuclear cells of the members of the family. env sequences of the viruses isolated from the patients were compared with sequences of HIV-1 subtype B viruses from Europe and local field isolates. Phylogenetic analysis revealed that the sequences of the viruses isolated from the patients were genetically related and formed an intrafamilial cluster of HIV-1 distinct from other subtype B viruses. Interindividual nucleotide variability in the C2-V3 and V4-C4-V5 domains ranged between 1.2 and 5.0% and between 2.2 and 7.5%, respectively, whereas divergence between HIV strains from the patients and control viral strains ranged from 6.6 to 29.3%. The amino acid signature patterns of viral clones from the three patients were closely related. In the C2-V3 region, two minor clones derived from the son's virus showed less nucleotide divergence (mean, 3.5 and 3.9%) than did the clones derived from the viruses of both parents or the seven other predominant clones derived from the virus from the son (mean, 5.4%). The top of the V3 loop of the last two clones and of all viral clones from the parents exhibited an unusual GPGG sequence. This is the first report of genotypic relatedness of HIV-1 in three adults of the same family in the absence of identified risk factor for transmission between the members of the family. Our findings suggest that atypical transmission of HIV may occur.
Subject(s)
Acquired Immunodeficiency Syndrome/transmission , HIV-1/genetics , Adult , Aged , Amino Acid Sequence , Female , HIV-1/classification , Humans , Male , Middle Aged , Molecular Sequence Data , Phylogeny , Risk FactorsABSTRACT
OBJECTIVES: To determine the clinical, virological and immunological outcome in a cohort of unselected patients receiving triple combination therapy for more than 1 year. METHODS: Prospective follow-up of a cohort of 162 unselected, protease inhibitor-naive, antiretroviral-experienced patients with advanced HIV disease, treated with indinavir combined with two nucleoside analogues. RESULTS: The mean CD4 cell count and plasma HIV RNA level in the study group at baseline were 69+/-5 x 10(6)/l and 4.75+/-0.07 log10 copies/ml, respectively. Five per cent of patients died prematurely or were lost to follow-up. Fifty-seven per cent of patients responded to therapy, as assessed by a sustained increase in CD4 cell counts above 50 x 10(6)/l and a decrease in plasma HIV RNA greater than 1 log10 copies/ml, throughout 12.1 months of follow-up. Seventeen per cent of patients were immunological and virological non-responders. Twenty-one per cent of patients exhibited discrepant virological and immunological responses to treatment, of whom one-half failed to exhibit significant increases in CD4 cells despite a virological response to therapy and one-half exhibited increased CD4 cell counts in the absence of significant decrease in plasma viral load. The incidence of AIDS-defining events in the latter group of patients was similar to that of responder patients, whereas their incidence was higher in patients who failed to exhibit a virological and immunological response and those who failed to increase CD4 cells despite a significant decrease in viral load. CONCLUSION: Our observations of discrepant immunological and virological responses to treatment raise the issue of the significance of persistent elevated levels of plasma HIV RNA and of the relevance of measurements of plasma viral load for assessing the efficacy of antiretroviral therapy in patients whose CD4 cell counts increase despite the absence of significant decrease in plasma HIV viral load.
Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV Protease Inhibitors/therapeutic use , Indinavir/therapeutic use , Lamivudine/therapeutic use , Reverse Transcriptase Inhibitors/therapeutic use , Stavudine/therapeutic use , Zidovudine/therapeutic use , Adult , Aged , Cohort Studies , Drug Therapy, Combination , Female , Follow-Up Studies , HIV Infections/immunology , HIV Infections/physiopathology , HIV Infections/virology , Humans , Male , Middle Aged , Prospective Studies , Treatment OutcomeSubject(s)
AIDS-Related Opportunistic Infections/immunology , Acquired Immunodeficiency Syndrome/drug therapy , Anti-HIV Agents/therapeutic use , CD4-Positive T-Lymphocytes/immunology , Cytomegalovirus Infections/complications , Acquired Immunodeficiency Syndrome/complications , Acquired Immunodeficiency Syndrome/immunology , Acute Disease , Adult , CD4 Lymphocyte Count , Cohort Studies , Cytomegalovirus Infections/immunology , Drug Therapy, Combination , Female , Follow-Up Studies , HIV Protease Inhibitors/therapeutic use , Humans , Male , Middle AgedSubject(s)
Cervix Uteri/virology , HIV Antibodies/analysis , HIV-1 , HIV-2 , Adult , Cross Reactions , Enzyme-Linked Immunosorbent Assay , Female , HumansABSTRACT
Adverse effects of zidovudine, which mainly result in myopathies and hematological disorders, could be due to multitissular mitochondrial toxicity of the drug. During zidovudine treatment, most cases of lactic acidosis have been attributed to mitochondrial myopathy. We report a case of hepatocellular failure with lactic acidosis in a 33 year-old patient with the human immunodeficiency virus infection and treated with zidovudine for 8 months. Liver biopsy showed massive macrovacuolar steatosis and ultrastructural mitochondrial abnormalities similar to those previously described in the skeletal muscle. This is the second reported case of lactic acidosis and hepatocellular failure which is probably related to hepatic mitochondrial dysfunction caused by zidovudine.
Subject(s)
Acidosis, Lactic/chemically induced , Anti-HIV Agents/adverse effects , Mitochondria, Liver/ultrastructure , Reverse Transcriptase Inhibitors/adverse effects , Zidovudine/adverse effects , Adult , HIV Infections/drug therapy , Humans , MaleABSTRACT
Plasma concentration of ganciclovir was studied prospectively in 15 AIDS patients treated for acute cytomegalovirus (CMV) retinitis. Ganciclovir was administered at a mean dose of 10.3 +/- 0.6 mg/kg/day. The mean trough plasma concentration was 0.6 +/- 0.3 mg/L (n = 24), and the mean peak concentration was 7.2 +/- 2.4 mg/L (n = 6). In 12 patients, trough concentrations were below the range that has been associated with effective treatment. Low trough concentrations were associated with treatment failure in 6 patients. Following an increase in the daily dose, improvement was observed in 4 of the 6 patients. These results suggest that low plasma ganciclovir levels are associated with the failure of therapy. Monitoring the plasma concentration of ganciclovir may thus be useful before considering the virus to be resistant to the drug or before switching from ganciclovir to foscarnet.
Subject(s)
AIDS-Related Opportunistic Infections/blood , Antiviral Agents/pharmacokinetics , Cytomegalovirus Infections/blood , Ganciclovir/pharmacokinetics , Retinitis/blood , AIDS-Related Opportunistic Infections/drug therapy , AIDS-Related Opportunistic Infections/virology , Acute Disease , Adult , Antiviral Agents/administration & dosage , Antiviral Agents/blood , Cytomegalovirus Infections/drug therapy , Cytomegalovirus Infections/virology , Ganciclovir/administration & dosage , Ganciclovir/blood , Humans , Male , Middle Aged , Prospective Studies , Retinitis/drug therapy , Retinitis/virologyABSTRACT
Paired sera and cervicovaginal secretions (CVS) from 11 HIV-1- and 11 HIV-2-infected women, all clinically asymptomatic (CDC A1 and A2 categories), were analyzed for total IgG, IgA, albumin (HSA), IgG, and IgA antibodies to env-encoded surface glycoproteins of HIV-1 (gp160) and of HIV-2 (gp105), by comparison to 15 age-matched healthy controls. Secretion rates of IgG and IgA into CVS were evaluated by calculation of their relative coefficients of excretion (RCE) by reference to HSA. Cervicovaginal production of anti-HIV antibodies was evaluated by comparison between specific antibody activities of IgG and of IgA to HIV in CVS were, respectively, 6- and 4-fold increased, whereas the secretion rate of total IgG was 2.1-fold increased and that of total IgA was 2.5-fold reduced. In contrast, total IgG and IgA as well as their secretion rates were normal in HIV-2-infected women. In HIV-1- but not in HIV-2-infected women, HSA levels in cervicovaginal washings were twofold increased, demonstrating alteration of the mucosal barrier in HIV-1 infection. In HIV-1-infected patients, IgG and IgA to gp160 were detected in all sera and CVS. In HIV-2-infected patients, IgG to gp105 was detected in all sera and CVS, whereas IgA to gp105 could be detected in only half of sera and one-third of CVS. Cross-reactivity by IgG and/or IgA to HIV-1 or HIV-2 against the surface glycoprotein of the other HIV type was observed in sera as well as in CVS, and more frequently in HIV-2- than in HIV-1-infected women. Finally, the mean specific activities of IgG and of IgA to gp160 or gp105 were higher in CVS than in sera, evidencing a possible local synthesis of both isotypes in HIV-1 as well as in HIV-2 infections. As early as the asymptomatic stages, HIV-1 affects the cervicovaginal mucosa more than HIV-2 does, suggesting higher viral replication within the female genital tract in HIV-1 infection than in HIV-2 infection.
Subject(s)
Cervix Uteri/immunology , HIV Antibodies/biosynthesis , HIV Infections/immunology , HIV-1/immunology , HIV-2/immunology , Immunoglobulin A/biosynthesis , Immunoglobulin G/biosynthesis , Vagina/immunology , Adult , Cervix Uteri/metabolism , Female , Gene Products, env/immunology , HIV Antibodies/blood , HIV Envelope Protein gp160/immunology , HIV Infections/classification , Humans , Immunoglobulin A/blood , Immunoglobulin G/blood , Middle Aged , Serum Albumin/analysis , Vagina/metabolism , env Gene Products, Human Immunodeficiency VirusSubject(s)
Desensitization, Immunologic , HIV Infections/drug therapy , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Dose-Response Relationship, Drug , Drug Hypersensitivity/immunology , HIV Infections/immunology , Humans , Trimethoprim, Sulfamethoxazole Drug Combination/adverse effects , Trimethoprim, Sulfamethoxazole Drug Combination/immunologyABSTRACT
Toxoplasmosis is the most common brain parasitic infection in acquired immunodeficiency syndrome (AIDS). Spinal cord localisations are still rare (2 cases with cerebral involvement, 2 cases without). A case of both spinal cord and cerebral involvement is reported. MR imaging was performed because of sensory level (L1). A focal conus medullaris enlargement was seen, iso intense on T1 weighted images. This lesion was hyperintense on T2 weighted sequence, and was homogeneously enhanced after Gadolinium on T1 weighted images. A medullary oedema was noted. A toxoplasmosis treatment was initiated, without corticotherapy. MR imaging performed one month later (D30), while important clinical improvements were seen, pointed out normal thickness of conus medullaris, without enhancement after Gadolinium. Disease lesions in AIDS with focal spinal cord processes are reviewed, and diagnostic work-up is discussed. Spinal cord single lesion, associated or not with brain involvements should be treated as a toxoplasmic infection, with MR imaging follow up. This work up should avoid medullary biopsy, still required in case of treatment failure. Cerebral involvements, with multiples lesions, can mask medullary localisation.